Description
Some HIV-1 carriers who have received an early antiretroviral treatment during several years are able to control the virus for a long term after treatment interruption. However, the mechanisms enabling this post-treatment control have not been fully elucidated. For the first time, teams of scientists from the Institut Pasteur, Inserm and the Paris Public Hospital Network (AP-HP), supported by ANRS | Emerging Infectious Diseases, have investigated and revealed how neutralizing antibodies, including those described as broadly neutralizing, contribute to virus control. These key findings were published in the journal Cell Host & Microbe on July 10, 2023. The RHIVIERA02 clinical trial involving the use of broadly neutralizing antibodies should begin in France before the end of 2023.
Keywords: HIV, remission, broadly neutralizing antibodies, Post-treatment controllers, PTC, ANRS VISCONTI study
